

Client: Example Client ABC123 123 Test Drive Salt Lake City, UT 84108 UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

202	
Gender:	Female
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

JAK2 (V617F) Mutation by ddPCR, Qualitative With Reflex to JAK2 Exon 12 Mutation Analysis by PCR

ARUP test code 3016840

JAK2 QUAL, Source	Extracted DNA	
JAK2 QUAL Mutation by PCR	Not Detected	
	The specimen submitted for testing did not meet ARUP submission guidelines. Testing was performed on a specimen that did not meet validated specimen type requirements. Performance characteristics of this assay may be affected. Interpret results with caution. Please refer to the ARUP Laboratory Test Directory for information on specimen acceptability: https://www.aruplab.com/testing	
	There is no evidence of the JAK2 V617F point mutation by ddPCR analysis. This result does not entirely exclude the possibility of a JAK2 V617F mutation below the test limit of detection.	
	JAK2 EX12 testing will be performed. Additional charges will apply.	
	This result has been reviewed and approved by	

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruptab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director



INTERPRETIVE INFORMATION: JAK2 (V617F) Mutation by ddPCR, Qualitative

This assay is designed to detect the point mutation c.1849G>T (V617F) of the JAK2 gene. JAK2 V617F mutations are present in patients with myeloproliferative neoplasms.

Methodology: DNA from whole blood or bone marrow specimens is amplified in an allele-specific droplet digital PCR (ddPCR) multiplex reaction targeting the JAK2 c.1849G>T single nucleotide mutation encoding the V617F mutation. The limit of detection for this assay is 0.5 percent mutated alleles.

Limitations: Variants in genes other than JAK2 are not detected. JAK2 variants other than V617F (c.1849G>T) are not reported. Samples with JAK2 V617F mutations below the limit of detection are not reported.

Results of this test must always be interpreted in the context of morphologic and other relevant data and should not be used alone for a diagnosis of malignancy.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

VERIFIED/REPORTED DATES					
Procedure	Accession	Collected	Received	Verified/Reported	
JAK2 QUAL, Source	25-066-402983	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
JAK2 QUAL Mutation by PCR	25-066-402983	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: Patient, Example ARUP Accession: 25-066-402983 Patient Identifiers: 01234567890ABCD, 012345 Visit Number (FIN): 01234567890ABCD Page 2 of 2 | Printed: 3/12/2025 1:56:39 PM 4848